Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-… Recruiting

2024-514409-78-01 relapsed / refractory or progressive high risk malignan 9 2019-07-26
BRCA-P: A Cancer Prevention study to determine if Denosumab can prevent Breast Cancer Development in Women carrying a BRCA1 Germline Mutatio… Recruiting

2024-513734-38-00 Prevention of breast cancer in women with a BRCA1 germl 5 2019-07-03
A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer (PEACE 4) Recruiting

2023-508072-11-00 Castration-resistant prostate cancer 5 2019-06-26
CETUXIMAB, IRINOTECAN AND FLUOROURACILE IN FIRST-LINE TREATMENT OF IMMUNOLOGICALLY-SELECTED ADVANCED COLORECTAL CANCER PATIENTS - the CIFRA … Recruiting

2024-518987-11-00 ADCC 4 2019-06-12
A clinical study to evaluate the safety, tolerability and early efficacy of the study drug (Durvalumab) alone and a combination of study dru… Recruiting

2023-510424-68-00 Advanced Solid Tumors 9 2019-05-28
An early study to investigate a new medicine for Subjects with Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) Recruiting

2024-515690-10-00 Follicular B-cell non-Hodgkin's lymphoma 9 2019-05-10
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Locally Advanced/Metastatic Urothelial Cancer 4 2019-05-07
The effect of androgen deprivation therapy on the expression of prostate specific membrane antigen (PSMA) in treatment naive metastatic pros… Recruiting

2024-519516-14-01 Metastatic prostate cancer, Prostate cancer 4 2019-04-15
A phase Ib/II randomized double-blind placebo controlled trial evaluating the effect of nivolumab for patients with in-transit melanoma meta… Recruiting

2023-509265-21-00 In-transit metastasis of malignant melanoma 4 2019-04-08
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
Atezolizumab After Chemo-radiotherapy for muscle-invasive bladder cancer Patients Not Eligible for Radical Cystectomy Recruiting

2024-512002-26-00 Muscle-invasive bladder cancer 4 2019-02-19
PHASE III TRIAL INVESTIGATING BENEFIT OF INTENSIFIED PERI-OPERATIVE CHEMOTHERAPY WITHIN HIGH-RISK CINSARC PATIENTS WITH RESECTABLE SOFT-TISS… Recruiting

2023-509489-39-00 Resectable, non-metastatic soft-tissue sarcoma (STS) 5 2019-02-05
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting

2024-518568-11-00 Hematological malignancies confirmed histologically: - 4 2019-02-04
Trial that evaluates the interest of interruption versus maintaining the treatment of aromatase inhibitors in patients with metastatic low g… Recruiting

2024-512629-97-00 Patients with locally advanced or metastatic low grade 4 2019-01-23
ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting

2023-506857-40-00 Prostate Cancer 5 2019-01-08
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21
A phase II study of Pembrolizumab plus Carboplatin in BRCA-related metastatic breast cancer Recruiting

2024-515686-34-00 BRCA-related metastatic breast cancer 4 2018-11-16
A study to compare conventional "salvage" radiotherapy and individualized treatment based on results from PSMA PET/CT assessments in patient… Recruiting

2023-504917-54-00 Biochemical recurrence after prostate cancer surgery 5 2018-10-30
Randomised trial evaluating mifamurtide in combination with standard chemotherapy in patients with high-grade osteosarcoma at high risk of r… Recruiting

2024-514780-26-00 Patients ≤50 years old with high-risk osteosarcoma (def 4 2018-10-23
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Study to Evaluate Efficacy and Safety of Multiple Treatment Combinations in Patients with Metastatic Breast Cancer (MORPHEUS-panBC) Recruiting

2023-503629-20-00 Metastatic breast cancer, including triple negative bre 9 2018-06-27
Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial Recruiting

2024-516585-11-00 Advanced melanoma 4 2018-06-12
Study to evaluate the therapeutic effect of a cell based immune therapy targeting cancer stem cells i the malignant brain tumor glioblastoma… Recruiting

2024-518663-35-00 Glioblastoma 10 2018-04-25
A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies Recruiting

2023-504880-18-00 Neuroblastoma (NBL) 9 2018-04-18